Abbott's last quarter 2014 results come in below estimates

29 January 2015
abbott-big

Currency fluctuations are a cause for concern for US health care company Abbott Laboratories (NYSE: ABT), as it reports its 2014 figures and looks to 2015.

The European Commission today cleared the sale of Abbott’s developed markets branded generic pharma business to Mylan (Nasdaq: MYL), which is expected to have a positive impact on subsequent earnings.

Sales for the fourth quarter stood at $5.36 billion, a 5.6% increase on the same quarter last year. Abbott's pharmaceutical division generated $922 million of sales, which was a 26.9% increase on the fourth quarter of 2013.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical